Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25189973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ayitila Maimaitijiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science (Institute of Materia Medica) & College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Drug Resistance, Multiple, Antineoplastic Agents. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Xinjiang Uygur Autonomous Region, the Key Research and Development Program in the Xinjiang Uygur Autonomous Region, Tianshan Talent Training Program.
Abstract (Originalsprache)
Chemotherapy has been widely applied in oncotherapy. However, the development of multidrug resistance (MDR) has diminished the effectiveness of anticancer drugs against tumor cells. Such resistance often results in tumor recurrence, metastasis, and patient death. Fortunately, nanoparticle-based drug delivery systems provide a promising strategy by codelivery of multiple drugs and MDR reversal agents and the skillful, flexible, smart modification of drug targets. Such systems have demonstrated the ability to bypass the ABC transporter biological efflux mechanisms due to drug resistance. Hence, how to deliver drugs and exert potential antitumor effects have been successfully explored, applied, and developed. Furthermore, to overcome multidrug resistance, nanoparticle-based systems have been developed due to their good therapeutic effect, low side effects, and high tumor metastasis inhibition. In view of this, we systematically discuss the molecular mechanisms and therapeutic strategies of MDR from nanotherapeutics. Finally, we summarize intriguing ideas and future trends for further research in overcoming MDR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science (Institute of Materia Medica) & College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
ORCID-Profile: Zhongxiong Fan, Jinyao Li
Förderung
- the Natural Science Foundation of Xinjiang Uygur Autonomous Region
- the Key Research and Development Program in the Xinjiang Uygur Autonomous Region
- Tianshan Talent Training Program
- and the Autonomous Region Universities Basic Research Funds Research Projects-Cultivation Projects
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- Key Research and Development Program in the Xinjiang Uygur Autonomous Region
- Autonomous Region Universities Basic Research Funds Research Projects-Cultivation Projects
Zitieren
APA
Maimaitijiang, A., He, D., Li, D., Li, W., Su, Z., Fan, Z., & Li, J. (2024). Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25189973
Vancouver
Maimaitijiang A, He D, Li D, Li W, Su Z, Fan Z, et al. Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25189973
BibTeX
@article{Maimaitijiang2024,
author = {Maimaitijiang, Ayitila and He, Dongze and Li, Dingyang and Li, Wenfang and Su, Zhengding and Fan, Zhongxiong and Li, Jinyao},
title = {Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25189973}
}
EUVIMED